{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:11:12Z","timestamp":1785409872877,"version":"3.56.0"},"reference-count":34,"publisher":"Veterinary World","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet. World"],"published-print":{"date-parts":[[2026,1,31]]},"abstract":"<jats:p>Background and Aim: Transforming growth factor-\u03b22 (TGF-\u03b22) and vascular endothelial growth factor (VEGF) are key mediators of inflammation, fibrosis, and angiogenesis in ocular surface disease. However, their roles in canine keratoconjunctivitis sicca (KCS) are not well understood. This study aimed to compare conjunctival TGF-\u03b22 and VEGF levels between healthy dogs and those with KCS, evaluate the effects of 6-week therapy with 0.2% cyclosporine A (CsA), and explore associations with clinical signs, Schirmer tear test-1 (STT-1), goblet cell density (GCD), and inflammatory cell infiltration. \n\nMaterials and Methods: Thirty-three dogs with KCS, classified as mild (n = 10), moderate (n = 10), or severe (n = 13), underwent ophthalmic exams, STT-1 measurements, and conjunctival biopsies before treatment (T0) and after 6 weeks of topical CsA therapy (T1). Fourteen healthy dogs served as controls. Conjunctival samples were analyzed for GCD, inflammatory cell counts, and TGF-\u03b22 and VEGF levels using histology and enzyme-Linked Immunosorbent Assay. Clinical scoring and corneal vascular quantification were performed using standardized protocols. Statistical comparisons were made within and between groups, as well as through correlation analyses. \n\nResults: CsA significantly increased STT-1 in all KCS grades and improved selected clinical signs. GCD in KCS dogs increased at T1, reaching levels comparable to controls, although not statistically significant. Neutrophils were the only inflammatory cells to significantly decrease after treatment. Overall, TGF-\u03b22 levels did not differ between controls and KCS dogs; however, concentrations increased with disease severity and showed a positive correlation with lymphocyte counts and corneal melanosis, and a negative correlation with GCD. VEGF levels were mildly elevated in KCS but decreased significantly following CsA treatment, especially in severe cases, and correlated positively with corneal melanosis and negatively with corneal vessel counts. A positive correlation was observed between TGF-\u03b22 and VEGF. \n\nConclusion: Topical 0.2% CsA improves tear production, GCD restoration, and various clinical signs in canine KCS. TGF-\u03b22 seems to have a pro-inflammatory and profibrotic role, increasing with disease severity and linked to chronic ocular surface changes. CsA effectively decreases VEGF, especially in severe KCS, indicating partial modulation of angiogenic pathways. Longer treatment durations may be necessary to influence TGF-\u03b22-mediated tissue remodeling. \n\nKeywords: canine keratoconjunctivitis sicca, cyclosporine therapy, goblet cell density, ocular surface inflammation, tear film biomarkers, transforming growth factor-\u03b22, vascular endothelial growth factor, veterinary ophthalmology.<\/jats:p>","DOI":"10.14202\/vetworld.2026.295-309","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:16:16Z","timestamp":1769411776000},"page":"295","update-policy":"https:\/\/doi.org\/10.14202\/vetworld.2022.policies","source":"Crossref","is-referenced-by-count":0,"title":["Conjunctival transforming growth factor-\u03b22 and vascular endothelial growth factor in canine keratoconjunctivitis sicca: Baseline alterations, clinical associations, and response to 0.2% cyclosporine therapy"],"prefix":"10.14202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2217-9518","authenticated-orcid":false,"given":"Bianca Eidt","family":"Rodrigues","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01mqvjv41","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Mato Grosso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-2886","authenticated-orcid":false,"given":"Alexandre Pinto","family":"Ribeiro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01mqvjv41","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Mato Grosso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-1133","authenticated-orcid":false,"given":"Tiago Barbalho","family":"Lima","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04ja5n907","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Estadual do Maranh\u00e3o"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-7298","authenticated-orcid":false,"given":"Alcyjara Rego","family":"Costa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04ja5n907","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Estadual do Maranh\u00e3o"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-0345","authenticated-orcid":false,"given":"Marvin Paulo","family":"Lins","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01mqvjv41","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Mato Grosso"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5847-2313","authenticated-orcid":false,"given":"Luis Jhordy Alfaro","family":"Quillas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01mqvjv41","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade Federal de Mato Grosso"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5308","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"ref0","unstructured":"1.\tGilger BC, Hendrix DVH, Kern TJ, Plummer CE, editors. Diseases and surgery of the canine lacrimal secretory system. In: Veterinary ophthalmology. 6th ed. Vol. II. Hoboken: John Wiley & Sons, Inc.; 2021. p. 1008\u20131044."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tBerdoulay A, English RV, Nadelstein B. Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. Vet Ophthalmol. 2005;8(4):225\u2013232.","DOI":"10.1111\/j.1463-5224.2005.00390.x"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tHendrix DV, Adkins EA, Ward DA, Stuffle J, Skorobohach B. An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs. Vet Med Int. 2011;2011:487592.","DOI":"10.4061\/2011\/487592"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tIzci C, Celik I, Alkan F, Erol M, Sur E. Clinical and light microscopic studies of the conjunctival tissues of dogs with bilateral keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine. Biotech Histochem. 2015;90(3):223\u2013230.","DOI":"10.3109\/10520295.2014.930177"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tRadziejewski K, Balicki I. Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. Acta Vet Hung. 2016;64(3):313\u2013329.","DOI":"10.1556\/004.2016.030"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tZulim LFDC, Nai GA, Giuffrida R, Cruz AG, Foglia BTD, Benguella H, et al. Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. Arq Bras Oftalmol. 2018;81(4):293\u2013301.","DOI":"10.5935\/0004-2749.20180059"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tMadruga GM, Ribeiro AP, Magalh\u00e3es TBS, Rondelli LAS, Furlan FH. Effects of 0.15% sodium hyaluronate and 0.5% carboxymethylcellulose on tear film breakup time in healthy dogs and in dogs with keratoconjunctivitis sicca. Arq Bras Med Vet Zootec. 2018;70(5):1388\u20131396.","DOI":"10.1590\/1678-4162-97330"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tFayad AR, Lobo TV, da Silva RH, Neves CA, Arnold E, Amorim A. Dry-eye syndrome in Shih Tzu dogs: Ocular surface clinical and morphological aspects in the different stages of keratoconjunctivitis sicca. Pesqui Vet Bras. 2023;43:e07270.","DOI":"10.1590\/1678-5150-pvb-7270"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tHachana S, Larriv\u00e9e B. TGF-\u03b2 superfamily signaling in the eye: Implications for ocular pathologies. Cells. 2022;11(15):2336.","DOI":"10.3390\/cells11152336"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tZheng X, De Paiva CS, Rao K, Pitcher JD, Farley WJ, Stern ME, et al. Evaluation of the transforming growth factor-beta activity in normal and dry eye human tears by CCL-185 cell bioassay. Cornea. 2010;29(9):1048\u20131054.","DOI":"10.1097\/ICO.0b013e3181cf98ff"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tPflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27(1):64\u201369.","DOI":"10.1097\/ICO.0b013e318158f6dc"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tDe Paiva CS, St Leger AJ, Caspi RR. Mucosal immunology of the ocular surface. Mucosal Immunol. 2022;15(6):1143\u20131157.","DOI":"10.1038\/s41385-022-00551-6"},{"key":"ref12","unstructured":"13.\tPhilipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41(9):2514\u20132522. PMID:10937562."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tBradley JC, Bradley RH, McCartney DL, Mannis MJ. Serum growth factor analysis in dry eye syndrome. Clin Exp Ophthalmol. 2008;36(8):717\u2013720.","DOI":"10.1111\/j.1442-9071.2008.01895.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tChan J, Lim G, Lee R, Tong L. A systematic review of tear vascular endothelial growth factor and external eye diseases. Int J Mol Sci. 2024;25(3):1369.","DOI":"10.3390\/ijms25031369"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tChennakesavalu M, Somala SRR, Dommaraju SR, Peesapati MP, Guo K, Rosenblatt MI, et al. Corneal lymphangiogenesis as a potential target in dry eye disease: A systematic review. Surv Ophthalmol. 2021;66(6):960\u2013976.","DOI":"10.1016\/j.survophthal.2021.03.007"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tWr\u00f3bel-Dudzi\u0144ska D, Przekora A, Kazimierczak P, \u0106wikli\u0144ska-Haszcz A, Kosior-Jarecka E, \u017barnowski T. The comparison between the composition of 100% autologous serum and 100% platelet-rich plasma eye drops and their impact on the treatment effectiveness of dry eye disease in primary Sj\u00f6gren syndrome. J Clin Med. 2023;12(9):3126.","DOI":"10.3390\/jcm12093126"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tTurgut B, Guler M, Akpolat N, Demir T, Celiker U. The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization. Curr Eye Res. 2011;36(1):34\u201340.","DOI":"10.3109\/02713683.2010.516620"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tPeriman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: The role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187\u20134200.","DOI":"10.2147\/OPTH.S279051"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tRadziejewski K, Balicki I, Szadkowski M. Assessment of corneal and conjunctival metaplasia by impression cytology during the treatment of canine keratoconjunctivitis sicca. Acta Vet Hung. 2018;66(2):189\u2013203.","DOI":"10.1556\/004.2018.018"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tMuellerleile LM, Bernkopf M, Wambacher M, Nell B. Topical bevacizumab for the treatment of corneal vascularization in dogs: A case series. Vet Ophthalmol. 2021;24(5):554\u2013568.","DOI":"10.1111\/vop.12931"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tOria AP, Pinna MH, Furtado MA, Pinheiro ACO, Gomes Junior DC, Costa Neto JM. Conjunctival microbiota in clinically healthy dogs and dogs with keratoconjunctivitis sicca. Cienc Anim Bras. 2013;14(4):495\u2013500.","DOI":"10.5216\/cab.v14i4.19210"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tPereira CSG, Zulim LFC, Giuffrida R, Cruz AG, Foglia BTD, Benguella H, et al. Antimicrobial susceptibility and minimal inhibitory concentration of bacteria isolated from the eyes of dogs with keratoconjunctivitis sicca. Pesqui Vet Bras. 2019;39(9):757\u2013763.","DOI":"10.1590\/1678-5150-pvb-6200"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tBenito MJ, Calder V, Corrales RM, Pflugfelder SC, Stern ME, Li DQ, et al. Effect of TGF-\u03b2 on ocular surface epithelial cells. Exp Eye Res. 2013;107:88\u2013100.","DOI":"10.1016\/j.exer.2012.11.017"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tMatsumura T, Fujimoto T, Futakuchi A, Ogawa Y, Murakami A, Ueta M, et al. TGF-\u03b2-induced activation of conjunctival fibroblasts is modulated by FGF-2 and substratum stiffness. PLoS One. 2020;15(11):e0242626.","DOI":"10.1371\/journal.pone.0242626"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tGum SI, Kim YH, Jung JC, Lee EJ, Kim MK, Park SH, et al. Cyclosporine A inhibits TGF-\u03b22-induced myofibroblasts of primary cultured human pterygium fibroblasts. Biochem Biophys Res Commun. 2017;482(4):1148\u20131153.","DOI":"10.1016\/j.bbrc.2016.12.002"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tIzci C, Celik I, Alkan F, Erol M, Sur E, Gungor E. Histologic characteristics and local cellular immunity of the gland of the third eyelid after topical ophthalmic administration of 2% cyclosporine for treatment of dogs with keratoconjunctivitis sicca. Am J Vet Res. 2002;63(5):688\u2013694.","DOI":"10.2460\/ajvr.2002.63.688"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tCordeiro MF. Role of transforming growth factor beta in conjunctival scarring. Clin Sci (Lond). 2003;104(2):181\u2013187.","DOI":"10.1042\/cs1040181"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tMcCauley HA, Liu CY, Attia AC, Nagineni CN, Zoukhri D, Kublin CL, et al. TGF\u03b2 signaling inhibits goblet cell differentiation via SPDEF in conjunctival epithelium. Development. 2014;141(23):4628\u20134639.","DOI":"10.1242\/dev.117804"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tDe Paiva CS, Volpe EA, Gandhi NB, Zhang X, Zheng X, Pitcher JD 3rd, et al. Disruption of TGF-\u03b2 signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. PLoS One. 2011;6:e29017.","DOI":"10.1371\/journal.pone.0029017"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.\tVinores SA, Chan CC, Vinores MA, Campochiaro PA, McCuskey RS, Csaky KG, et al. Increased vascular endothelial growth factor and transforming growth factor beta in experimental autoimmune uveoretinitis: Upregulation of VEGF without neovascularization. J Neuroimmunol. 1998;89(1\u20132):43\u201350.","DOI":"10.1016\/S0165-5728(98)00075-7"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tBian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res. 2007;84(5):812\u2013822.","DOI":"10.1016\/j.exer.2006.12.016"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"33.\tNagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wang L, Tsai JY, et al. Transforming growth factor-beta induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: Involvement of mitogen-activated protein kinases. J Cell Physiol. 2003;197(3):453\u2013462.","DOI":"10.1002\/jcp.10378"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tOgata FT, Verma S, Coulson-Thomas VJ, Gesteira TF. TGF-\u03b2-based therapies for treating ocular surface disorders. Cells. 2024;13(13):1105.","DOI":"10.3390\/cells13131105"}],"container-title":["Veterinary World"],"original-title":[],"link":[{"URL":"https:\/\/veterinaryworld.org\/Vol.19\/January-2026\/21.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T07:16:22Z","timestamp":1769411782000},"score":1,"resource":{"primary":{"URL":"https:\/\/veterinaryworld.org\/Vol.19\/January-2026\/21.php"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":34,"URL":"https:\/\/doi.org\/10.14202\/vetworld.2026.295-309","relation":{},"ISSN":["0972-8988","2231-0916"],"issn-type":[{"value":"0972-8988","type":"print"},{"value":"2231-0916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"article-number":"21"}}